Identification of a Bipolar Disorder Vulnerable Gene CHDH at 3p21.1 by Chang, Hong et al.
1 
 
Replication BPD Sample Information 
 
Among all the tested European samples, both BPD patients and healthy controls 
provided written informed consent prior to their inclusion in the respective studies. 
All protocols used in the original studies reporting these samples were approved by 
the relevant ethical review bodies, and followed all applicable institutional, national 
and international guidelines.  
 
Romania sample 
The Romania sample consisted of 380 BPD patients and 223 healthy controls. All 
patients were recruited from consecutive hospital admissions and directly interviewed 
with the Structured Clinical Interview for DSM-IV-TR-Axis I Disorders - Patient 
Version (SCID-I, 1994) and the Diagnostic Interview for Genetic Studies (DIGS) 
version 3.0 (1999). Information provided by medical records and interviews of family 
members was also used in a best estimate procedure of diagnosis on the basis of 
DSM-IV-TR criteria. The control sample was population-based, drawn from the same 
population as the patients, and was screened for major psychiatric disorders prior to 
inclusion. The ethnicity of the patients and control subjects was determined by 
genealogical investigation to the grandparental generation. Only the patient sample 
was previously reported in other collaborative studies (Cichon et al, 2011; Hammer et 
al, 2012; Vassos et al, 2012). The controls were genotyped on Illumina 
OMNI-Express chips at the Life & Brain Center in Bonn, and the patients were also 
genotyped on Illumina chips (partly on Omni1-Quad). 
 
Sweden I sample 
The Sweden I sample consisted of 836 cases and 2,093 controls collected from the 
following cohorts. St. Göran Bipolar (SBP) cases were recruited from St. Göran’s 
Hospital in Stockholm, Sweden. All participants provided written informed consent to 
participate in a genetic study of BPD, and the study was approved by the Regional 
Ethics Committee of Stockholm. Diagnoses were based on physician administered 
ADE (Spitzer et al, 1992) and MINI (Sheehan et al, 1998).  
BipoläR cases were identified from the Swedish Bipolar Quality Assurance 
Registry (BipoläR). Patient information within the registry includes disease 
sub-classification, psychosis, age at onset, number of manic and depressive episodes, 
number of hospitalizations and family history. Participants provided written informed 
consent to participate in a genetic study of psychiatric disease, and the study was 
approved by the Regional Ethics Committee of Stockholm.   
Hospital Discharge Registry (HDR) bipolar cases were identified from the 
Swedish Hospital Discharge Registry if they a) have at least two admissions with 
discharge diagnoses of BPD and b) were born in Sweden or another Nordic country. 
The register contains a nearly complete record of all individuals hospitalized in 
Sweden since 1973. Diagnoses were established by an attending physician and were 
shown to have high sensitivity and specificity (Sellgren et al, 2011). The study was 
approved by the Regional Ethics Committee of Stockholm. All participants provided 
written informed consent to participate in genetic studies of psychotic disorders and 
were interviewed by a research nurse about other medical conditions.   
The Swedish Bipolar Study Group (SBSG) cases were recruited from the 
Stockholm County catchment area. All patients provided written informed consent to 
participate in a genetic study of BPD, and the study was approved by the Regional 
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Ethics Committee of Stockholm. Diagnoses were made according to the DSM-IV 
criteria.  
Sweden control samples were obtained from the Swedish Hospital Discharge 
Registry on the condition they had never received discharge diagnoses of BPD, 
schizophrenia and/or schizoaffective disorder.  
 
Sweden II sample 
This sample consisted of 1,415 patients with BPD (62.5% female, age ± SD = 53 
± 14, BPD type I =578, BPD type II= 517, NOS=281, SAB = 39, unknown subtype = 
4), and 1,271 healthy controls (50.3% female, age ± SD= 59 ± 11 years). All subjects 
were unrelated to each other and ethnically Swedish. Patients with BPD were 
collected from the Swedish National Quality Assurance Registry for bipolar disorder 
(BipoläR), to which all patients with a DSM-IV diagnosis of bipolar I, II, NOS, or 
schizoaffective disorder are considered for registration at the participating clinics 
(Sellgren et al, 2011). There were no other inclusion or exclusion criteria. Diagnoses 
were made by the treating physician with longitudinal access to all available clinical 
information. Controls were also identified from national population registers, and had 
never received a discharge diagnosis of SCZ or bipolar disorder. Controls were 
contacted directly in a similar procedure as the cases, gave written informed consent, 
were interviewed about other medical conditions and visited their family doctor or 
local hospital laboratory for blood donation. Patients and controls were genotyped on 
the Illumina Omni Express array, and the genomic inflation factor (lambda) is 1.03. 
 
France sample 
The France sample included 451 BPD patients and 1,631 healthy controls. Both 
BPD and controls were recruited as part of a large study on genetics of BPD in France 
(Paris-Creteil, Bordeaux, Nancy) with a protocol approved by relevant IRBs and with 
written informed consent. Patients with BPD were in remission at the time of their 
inclusion, and were all of French descent dated back to three generations. All patients 
were assessed by a trained psychiatrist or psychologist using the DIGS (Nurnberger et 
al, 1994) and FIGS. Diagnoses were based on structured interviews supplemented by 
medical case notes, mood scales and a self-rating questionnaire assessing dimensions. 
Genotyping of controls were provided by the Centre National de Génotypage (M 
Lathrop, Evry). Patients and controls were genotyped on the Illumina platform 
(HumanHap300, HumanHap550, HumanHap 610-quad).  
 
Germany II and III sample 
Cases for Germany II and III samples were ascertained from consecutive 
admissions to the psychiatric inpatient units at the University Hospital Würzburg and 
at the Central Institute for Mental Health in Mannheim, University of Heidelberg, as 
well as at other collaborating psychiatric university hospitals in Germany. DSM-IV 
lifetime diagnoses of BPD were assigned using a consensus best-estimate procedure, 
based on all available information, including structured interviews (SCID-I, SADS-L; 
Germany III) or semi-structured interviews (AMDP; Germany II), medical records, 
and the family history method. In addition, the OPCRIT system was used for the 
detailed polydiagnostic documentation of symptoms (McGuffin et al, 1991). 
Controls for Germany II were ascertained from the population-based Heinz 
Nixdorf Recall Study (Schmermund et al, 2002). Study protocols were reviewed and 
approved in advance by Institutional Review Boards of the participating institutions.  
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The controls for Germany III were recruited at the Max Planck Institute of 
Psychiatry in Munich, Germany, and were selected randomly from a Munich-based 
community sample. They were collected in the course of genetic studies of major 
depression, and were therefore screened for the presence of anxiety and affective 
disorders using the Composite International Diagnostic Screener (WHO-CIDI). Only 
individuals negative for the above-named disorders were included in the sample. All 
included controls were Caucasian, 93.04% were of German origin. These subjects 
thus represent a group of healthy individuals with regard to depression and anxiety. 
The study was approved by the ethics committee of the Ludwig Maximilians 
University in Munich, Germany. 
All subjects provided written informed consent and were genotyped using the 
Illumina platform.  
 
Australia sample 
The Australia sample included 330 BPD patients and 1,811 healthy controls. 
Subjects were ascertained through two studies: 1) a BPD pedigree sample (described 
in McAuley et al. (McAuley et al, 2009)) and 2) a specialized Sydney Black Dog 
Institute BPD clinic sample (described in Mitchell et al. 2009) (Mitchell et al, 2009). 
All subjects were interviewed by trained research staff using the DIGS or SCID, using 
best-estimate DSM-IV diagnoses derived from those instruments, medical records and 
FIGS. First, for the pedigree sample, only one BPD subject per family was included in 
the case sample. Pedigrees were only included in the original genetic study if there 
was unilineal inheritance, and at least two BPD subjects including at least one with 
bipolar I disorder. Subjects were ascertained through clinical presentations to the 
Mood Disorders Unit at the Prince of Wales Hospital in Sydney, direct referrals from 
Australian clinicians, and BPD consumer organizations. Second, for the clinic sample, 
subjects comprised consecutive subjects referred by psychiatrists or general 
practitioners for specialized clinical review. All patients provided written informed 
consent to participate in this study and the study was approved by the local ethics 
committee. Patients were included in the MooDS study and genotyped at the Life & 
Brain Center in Bonn using the Illumina platform.   
Australia controls were drawn from families participating in the Brisbane 
Longitudinal Twin Study, an unselected community sample recruited to take part in 
studies of melanoma risk factors, cognition, and other phenotypes. Subjects were not 
screened for any phenotype relevant to BPD. The study was approved by the ethic 
committee and all proband gave written informed consent. All subjects were 
genotyped as a single project by deCODE using the Illumina platform and have been 
through an extensive QC process including exclusion for non-European ancestry. The 
sample is overwhelmingly of northern European origin, predominately from the 
British Isles. 
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Analyses of temporal-spatial expression pattern of CHDH in human brain 
To determine the temporal-spatial expression of CHDH in the human brain, we 
extracted expression data of CHDH from Human Brain Transcriptome (HBT) (Kang 
et al, 2011) and BrainCloud (Colantuoni et al, 2011) databases. The HTB database 
includes transcriptome of 16 regions comprising the cerebellar cortex, mediodorsal 
nucleus of the thalamus, striatum, amygdala, hippocampus, and 11 areas of the 
neocortex. In total, 1,340 tissue samples were collected from 57 developing and adult 
post-mortem brains. The Brain Cloud database (http://braincloud.jhmi.edu/) contains 
genome-wide gene expression data from the human postmortem dorsolateral 
prefrontal cortex (DLPFC) of normal subjects (N=261) across the lifespan. More 
detailed information can be found in the original publications (Colantuoni et al, 2011; 
Kang et al, 2011). 
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Table S1. Description of individual samples included in this study 
Sample Cases Case diagnosis Diagnosis Interview Controls Genotyping λ 
Discovery        
PGC1 7,481 BPD1,BPD2,SAB,BPD-NOS DSMIIR,DSM-IV,RDC multiple 9,250 multiple 1.15 
Replication        
Romania 380 BPD1 DSM-IV SCID-I-P/DIGS 223 Illumina / 
Sweden I 836 BPD1,BPD2,BPD-NOS DSM-IV ADE,MINI 2,093 Affymetrix 6.0 1.07 
Sweden II 1,415 BPD1,BPD2,SAB,BPD-NOS DSM-IV / 1,271 Affymetrix 6.0 1.03 
France 451 BPD1,BPD2,BPD-NOS DSM-IV DIGS 1,631 Illumina 1.03 
Germany II 181 BPD1,BPD2 DSM-IV AMDP 527 Illumina 1.05 
Germany III 490 BPD1,BPD2, BPD-NOS DSM-IV 
AMDP, CID-S, 
SCID-I,SADS-L 
880 Illumina 1.00 
Australia 330 BPD1,BPD2,SAB,BPD-NOS DSM-IV SCID,DIGS 1,811 Illumina 1.00 
 
Abbreviations:  
BPD1, bipolar disorder type 1; BPD2, bipolar disorder type 2; BPD-NOS, bipolar disorder not otherwise specified; 
SAB, schizoaffective disorder (bipolar type); λ = genomic control lambda. 
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Table S2. Association of CHDH SNPs with BPD in the PGC discovery sample 
SNP Position Allele 1 Allele 2 Frequency P-value OR SE 
rs3774605 53805807 A G 0.3607 1.88E-05 0.8962 0.0256 
rs3774608 53807752 A G 0.4016 3.84E-06 0.8894 0.0254 
rs3774609 53807943 G T 0.418 2.56E-06 0.8878 0.0253 
rs3796349 53808549 A G 0.9344 0.9406 1.0041 0.0552 
rs2359133 53811782 C G 0.6393 0.000852 1.0849 0.0244 
rs2359132 53811977 A G 0.9426 0.9623 0.9974 0.0546 
rs870280 53812286 C T 0.0492 0.6143 1.0293 0.0574 
rs4687586 53813011 C G 0.6803 0.000642 1.0902 0.0253 
rs6766988 53814510 A T 0.0984 0.4011 0.9661 0.0411 
rs3774614 53816504 C T 0.4508 0.000598 0.9216 0.0238 
rs877484 53821964 A G 0.4262 0.000802 0.924 0.0236 
rs893363 53822102 A G 0.6148 0.000629 1.0883 0.0247 
rs14165 53822448 A G 0.3115 0.000873 0.9195 0.0252 
rs881883 53822845 A G 0.8852 0.8163 0.9906 0.0406 
rs4687587 53824550 A G 0.3115 0.002653 0.927 0.0252 
rs11130381 53825045 C T 0.4426 0.005213 0.9361 0.0236 
rs4687744 53825279 C G 0.9508 0.5753 0.9684 0.0574 
rs4563403 53825854 C T 0.8852 0.9769 0.9989 0.0392 
rs2289209 53827875 C T 0.9672 0.7222 0.98 0.0569 
rs7625247 53829108 G T 0.582 0.008704 1.0645 0.0238 
rs9836592 53830123 C T 0.3443 0.002321 0.9258 0.0253 
rs6445606 53831090 C T 0.3361 0.001928 0.9238 0.0256 
rs2241807 53832198 C T 0.4426 0.008085 0.9392 0.0237 
rs9001 53832957 G T 0.082 0.4201 1.0389 0.0473 
rs2276838 53833204 C T 0.4426 0.00836 0.9394 0.0237 
rs7626693 53833581 C T 0.459 0.01367 0.9431 0.0238 
rs9835128 53835143 A C 0.1066 0.1008 1.0661 0.039 
rs13317328 53845880 A C 0.877 0.1877 0.9363 0.05 
rs11718497 53847057 C G 0.377 0.2054 0.9695 0.0244 
rs920253 53847793 G T 0.9918 0.6157 1.0711 0.1369 
rs930367 53848618 C T 0.0492 0.1372 1.1122 0.0716 
rs6801605 53851258 A G 0.3443 0.3331 0.9771 0.0239 
rs6445607 53852189 G T 0.3689 0.3568 0.9782 0.024 
rs6445608 53852273 C G 0.6311 0.3377 1.0233 0.0241 
rs3774616 53852973 C T 0.0574 0.04885 1.1599 0.0753 
rs2289207 53853424 C T 0.9672 0.3 1.1219 0.111 
rs17641133 53853637 A T 0.2541 0.1088 0.9581 0.0267 
rs2289205 53853656 C T 0.7377 0.1206 1.045 0.0283 
rs7627178 53856511 A G 0.6639 0.2527 1.0296 0.0255 
rs1025690 53857703 A G 0.6885 0.07896 1.0471 0.0262 
rs2276839 53857943 C G 0.2623 0.1063 0.9575 0.0269 
rs1025689 53858762 C G 0.3279 0.3215 0.9749 0.0257 
rs4687751 53858950 C T 0.3443 0.3144 0.9745 0.0257 
rs9878562 53864028 C T 0.5246 0.8418 1.0046 0.0231 
rs999514 53864889 C T 0.4344 0.8612 0.9958 0.0239 
rs999515 53865021 C T 0.3607 0.9145 1.0027 0.0248 
rs2276840 53866137 C G 0.6066 0.8288 1.0053 0.0244 
rs2276841 53866163 A G 0.8852 0.8539 0.993 0.0379 
rs9840079 53867681 G T 0.4918 0.893 0.9969 0.0231 
rs2232345 53867760 A T 0.0492 0.5048 0.9505 0.0761 
rs3821869 53868880 A C 0.377 0.846 0.9953 0.0244 
rs6766099 53869452 C T 0.9016 0.9892 0.9995 0.0381 
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Table S3. Genes differentially expressed between BPD patients and healthy 
controls 
 
 RNA-seq analyses Microarray analyses 
 Akula et al. (2014) Zhao et al. (2015) Akula et al. (2014) Seifuddin et al. (2013) 
Genes P-value P-value P-value P-value 
Up-regulated     
ALDH4A1 0.000124 0.00615 0.0470 n.s. 
PBXIP1 0.000824 0.00267 n.s. 0.0526 
GALM 0.00736 0.00868 n.s. n.s. 
CHDH 0.00811 0.00251 0.00497 0.0361 
TP53BP2 0.00855 0.00452 n.s. 0.00171 
     
Down-regulated     
VIP 0.00421 0.00124 0.00625 n.s. 
HIVEP2 0.00646 0.00175 n.s. 0.00997 
FAM49A 0.00905 0.00363 0.0281 n.s. 
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Table S4. Association of rs9836592 [T] with BPD in different European samples 
Sample N_Case N_Control P-value OR 95%CI 
Discovery 7,481 9,250 0.00232 1.080 [1.028; 1.135] 
Romania 380 223 0.0555 1.217 [0.956; 1.551] 
Sweden I 836 2,093 0.498 1.000 [0.884; 1.131] 
Sweden II 1,415 1,271 0.137 1.073 [0.946; 1.218] 
France 451 1,631 0.248 1.064 [0.890; 1.271] 
Germany II 181 527 0.0836 1.209 [0.924; 1.583] 
Germany III 490 880 0.0757 1.128 [0.957; 1.330] 
Australia 330 1,811 0.169 0.917 [0.768; 1.095] 
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Table S5. Association of rs9836592 with CHDH’s nearby gene expression in 
several tissues. P-value is shown in the table. 
 
 
 
 
 
 
 
  CACNA1D IL17RB ACTR8 SELK 
Cerebellum 0.64 0.12 0.81 0.85 
Cerebellar Hemisphere 0.77 0.10 0.036 0.55 
Putamen 0.096 0.34 0.00038 0.35 
Nerve Tibial 0.53 9.8×10-15 0.59 0.085 
Hypothalamus 0.58 0.0078 0.0020 0.45 
Hippocampus 0.82 0.70 0.13 0.16 
Muscle Skeletal 0.063 0.44 0.057 0.30 
Thyroid 0.86 0.00061 0.015 0.96 
Testis 0.20 0.79 0.013 0.10 
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Figure S1. The locations and LD patterns of rs2251219 and rs9836592 in European populations. 
 
 
 
 
11 
 
Figure S2. Association of rs9836592 with the expression of genes in BrainCloud 
(Colantuoni et al, 2011). 
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Figure S3. Spatial expression profiling of CHDH in human brain tissues from GTEx (GTEx Consortium, 2013). 
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Figure S4. Temporal expression profiling of CHDH in human brain DLPFC from 
BrainCloud (Colantuoni et al, 2011). 
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Figure S5. Temporal expression pattern of CHDH in different human brain 
regions in Human Brain Transcriptome (Kang et al, 2011). 
 
Notes: AMY, amygdala; CBC, cerebellar cortex; HIP, hippocampus; MD, mediodorsal 
nucleus of the thalamus; NCX, neocortex; STR, striatum. 
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